On August 3, 2021, Tenaya Therapeutics, a biotechnology company with a mission to discover, develop, and deliver curative therapies that address the underlying causes of heart disease, announced the closing of its underwritten, upsized initial public offering of 13,800,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,800,000 additional shares of its common stock, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering were $207.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Tenaya. All shares in the offering were offered by Tenaya. The shares began trading on the Nasdaq Global Select Market on July 30, 2021, under the ticker symbol “TNYA.”
The Wilson Sonsini Goodrich & Rosati team that advised Tenaya Therapeutics on the transaction includes:
Corporate
Ken Clark
Jennifer Knapp
Jennifer Fang
Emily Coskey
Priyanka Nawathe
Tamara Labanowski
Marianne Stark Bradley
Jennifer Gu
Technology Transactions
Matt Wiltermuth
David Pirko
Colin Bosch
Regulatory and Compliance
David Hoffmeister
Eva Yin
Patents and Innovations
Mike Hostetler
Uale Taotafa
Jennifer Floyd
Employee Benefits and Compensation
Matt Norgard
Privacy and Cybersecurity
Matt Staples
Michael O’Brien
For more information, please see Tenaya's press release.